Ads
related to: macular degeneration medication warnings treatment options reviews and cost
Search results
Results From The WOW.Com Content Network
Anti–vascular endothelial growth factor therapy, also known as anti-VEGF (/ v ɛ dʒ ˈ ɛ f /) therapy or medication, is the use of medications that block vascular endothelial growth factor. This is done in the treatment of certain cancers and in age-related macular degeneration.
These drugs are approved to treat neovascular (wet) age-related macular degeneration, macular edema following retinal vein occlusion, diabetic macular edema and diabetic retinopathy. View the ...
Ranibizumab, sold under the brand name Lucentis among others, is a monoclonal antibody fragment created from the same parent mouse antibody as bevacizumab.It is an anti-angiogenic [16] that is approved to treat the "wet" type of age-related macular degeneration (AMD, also ARMD), diabetic retinopathy, and macular edema due to branch retinal vein occlusion or central retinal vein occlusion.
Conbercept is a soluble receptor decoy that binds specifically to VEGF-B, placental growth factor (PlGF), and various isoforms of VEGF-A. [1] [4] [15] Conbercept has a VEGF-R2 kinase insert domain receptor (KDR) Ig-like region 4 (KDRd4) which improves the three-dimensional structure and efficiency of dimer formation, thereby increasing the binding capacity of conbercept to VEGF.
Once inside, the therapeutic genes are expressed to address genetic deficiencies or modify biological pathways, offering a long-term or potentially permanent treatment ("biofactory approach") for conditions like wet age-related macular degeneration (AMD), diabetic macular edema, and inherited retinal dystrophies. [2]
Aflibercept, sold under the brand names Eylea and Zaltrap among others, is a medication used to treat wet macular degeneration and metastatic colorectal cancer. [14] [15] It was developed by Regeneron Pharmaceuticals. It is an inhibitor of vascular endothelial growth factor (VEGF).